公司演示-康寧傑瑞

English 中文简体中文繁体

English 中文简体中文繁体

投資者關系

信息披露

公司治理

股票信息

投資者查詢

電郵訂閱

公司演示

2020世界肺癌大會壁報-KN046用於治療晚期非小細胞肺癌(NSCLC)患者的Ⅱ期臨床研究數據 2021-02-01
2020世界肺癌大會迷妳口頭報告-KN046在罕見胸部腫瘤患者中的初步安全性和有效性結果 2021-02-01
公司演示材料更新 2021-01-21
ASCO-GI poster-KN046聯合放化療治療復發和轉移性食管鱗癌的初步療效和安全性數據 2021-01-18
2020 Jefferies倫敦線上醫療投資峰會演示材料 2020-11-16
SITC poster - Preliminary Safety, Tolerability and Efficacy Results of KN026 in combination with KN046 in Patients with HER2 aberrated solid tumors 2020-11-12
第27屆CITIC CLSA年度投資峰會演示材料 2020-09-22
2020 Interim Result Investor Presentation 2020-08-28
Company recent development report - July 2020 2020-07-30
AACR poster #1181 - Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody 2020-06-22
2020 Jefferies Virtual Healthcare Conference 2020-06-02
ASCO poster #3021 - Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency 2020-05-29
ASCO poster #1041 - Preliminary Safety, Efficacy and Pharmacokinetics (PK) Results of KN026, a HER2-targeted Bispecific Antibody in Patients (pts) with HER2-positive Metastatic Breast Cancer 2020-05-29
ASCO poster #3020 - The preliminary efficacy and safety data of KN046 (bispecific anti-PD-L1/CTLA4) in patients failed on prior immune checkpoint inhibitors therapy 2020-05-29
Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody 2020-05-28
Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency 2020-05-28
The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy 2020-05-17
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer 2020-05-17